These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34696815)

  • 1. High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.
    Zhao Y; Su W; Liang G; Shan X; Ma W; Tang D; Li L; Niu X; Zhao S; Zhang Q; Zhao W
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):63. PubMed ID: 34696815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
    Liang G; Ma W; Zhao Y; Liu E; Shan X; Ma W; Tang D; Li L; Niu X; Zhao W; Zhang Q
    BMC Cancer; 2021 Apr; 21(1):362. PubMed ID: 33827689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity.
    Pease DF; Peterson BA; Gilles S; Hordinsky MK; Bohjanen KA; Skubitz KM
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):217-221. PubMed ID: 31041511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome.
    Lian J; Tang X; Gui Y; Lu S; Song Y; Deng Y
    Int J Pharm; 2024 Nov; 665():124659. PubMed ID: 39260752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
    Bun S; Yunokawa M; Tamaki Y; Shimomura A; Shimoi T; Kodaira M; Shimizu C; Yonemori K; Fujiwara Y; Makino Y; Terakado H; Tamura K
    Support Care Cancer; 2018 Jul; 26(7):2161-2166. PubMed ID: 29372396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
    Mrochen-Domin I; Nowara E; Kaleta B
    Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
    Schmitt CJ; Dietrich S; Ho AD; Witzens-Harig M
    Ann Hematol; 2012 Mar; 91(3):391-7. PubMed ID: 21850390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin.
    Hu X; Dong M; Liang X; Liu Z; Li Q
    Int J Nanomedicine; 2021; 16():471-480. PubMed ID: 33500617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin.
    Nara K; Taguchi A; Yamamoto T; Tsuruga T; Tojima Y; Miyamoto Y; Tanikawa M; Sone K; Mori M; Takada T; Suzuki H; Osuga Y
    Support Care Cancer; 2023 Apr; 31(5):283. PubMed ID: 37074471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
    Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
    Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
    Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO)
    Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):617-623. PubMed ID: 32867451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
    Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
    In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.